Authors:
Martinetti, A
Ferrari, L
Celio, L
Mariani, L
Miceli, R
Zilembo, N
Di Bartolomeo, M
Toffolatti, L
Pozzi, P
Seregni, E
Bombardieri, E
Bajetta, E
Citation: A. Martinetti et al., The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers, J STEROID B, 75(1), 2000, pp. 65-73
Authors:
Bajetta, E
Di Bartolomeo, M
Stani, SC
Artale, S
Ricci, SB
Bozzetti, F
Mazzaferro, V
Toffolatti, L
Buzzoni, R
Citation: E. Bajetta et al., Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: Results of a feasibility study, INT J RAD O, 45(2), 1999, pp. 285-289
Authors:
Di Bartolomeo, M
Bajetta, E
Buzzoni, R
Bozzetti, F
Artale, S
Valvo, F
Citation: M. Di Bartolomeo et al., Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study, TUMORI, 85(3), 1999, pp. 211-213
Authors:
Bajetta, E
Ferrari, L
Martinetti, A
Celio, L
Procopio, G
Artale, S
Zilembo, N
Di Bartolomeo, M
Seregni, E
Bombardieri, E
Citation: E. Bajetta et al., Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors, CANCER, 86(5), 1999, pp. 858-865